###begin article-title 0
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR16-1</italic>
Investigation of the miR16-1 (C > T) + 7 Substitution in Seven Different Types of Cancer from Three Ethnic Groups
###end article-title 0
###begin p 1
Recommended by Boffetta Paolo
###end p 1
###begin p 2
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Background</italic>
###xml 233 240 233 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR16-1</italic>
###xml 401 408 401 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR16-1</italic>
###xml 437 442 437 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bcl-2</italic>
###xml 608 615 608 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR16-1</italic>
###xml 717 724 717 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR16-1</italic>
###xml 1134 1141 1134 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</italic>
###xml 1238 1245 1238 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Results</italic>
###xml 1331 1342 1331 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conclusions</italic>
###xml 1482 1490 1482 1490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-16-1</italic>
###xml 197 202 <span type="species:ncbi:9606">human</span>
###xml 334 342 <span type="species:ncbi:9606">patients</span>
###xml 822 830 <span type="species:ncbi:9606">patients</span>
Background. MicroRNAs are a type of small noncoding RNA molecules that have been shown to control gene expression in eukaryotes. Aberrant expression and alteration of miRNAs may be responsible for human diseases including cancer. An miR16-1 (C > T) + 7 gene mutation has been previously found in familial chronic lymphocytic leukemia patients, one of which reported a family history of breast cancer. miR16-1 regulates the expression of bcl-2, which is important in retinoblastoma, and is located in a genomic region that is frequently lost in nasopharyngeal and hepatocellular carcinomas (HCCs). Therefore, miR16-1 may be potentially important in the etiology of several solid tumors. To understand the power of the miR16-1 (C > T) + 7 mutation as a prognostic and diagnostic risk factor, we investigated the mutation in patients with seven different types of cancer including 188 with breast, 102 with ovarian, and 22 nasopharyngeal carcinomas, 96 HCC, 872 chronic myeloid leukemia (CML), 39 chronic lymphocytic leukemia (CLL), and 46 retinoblastoma cases from three different ethnic groups and of hereditary and sporadic etiology. Methods. 5'Nuclease TaqMan SNP genotyping assay was used to detect the miR16-1 gene C > T substitution. Results. The miR16-1 (C > T) + 7 substitution was not detected in any of the groups studied. Conclusions. Considering the large scale of our study, the representation of different ethnicities and levels of hereditary risk, we conclude that the miR-16-1 (C > T) + 7 mutation is not a good diagnostic or prognostic indicator of risk for the cancers tested.
###end p 2
###begin title 3
1. Introduction
###end title 3
###begin p 4
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 348 349 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 351 352 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 535 536 535 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 618 619 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 630 631 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 710 718 710 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-16-1</italic>
###xml 792 797 792 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bcl-2</italic>
###xml 892 893 892 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 925 932 925 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR16-1</italic>
###xml 937 943 937 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR15a</italic>
###xml 1190 1197 1190 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-15a</italic>
###xml 1202 1210 1202 1210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-16-1</italic>
###xml 1317 1324 1317 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-15a</italic>
###xml 1329 1337 1329 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-16-1</italic>
###xml 1381 1386 1381 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 1462 1464 1462 1464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rb</italic>
###xml 1756 1757 1756 1757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1929 1930 1929 1930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 2052 2053 2052 2053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 2195 2197 2195 2197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 2292 2294 2292 2294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 2681 2688 2681 2688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR16-1</italic>
###xml 241 246 <span type="species:ncbi:9606">human</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
###xml 2377 2385 <span type="species:ncbi:9606">patients</span>
###xml 2504 2512 <span type="species:ncbi:9606">patients</span>
MicroRNAs are a group of small noncoding RNA (ncRNA) molecules that have been identified in many organisms [1, 2] and shown to regulate the expression of genes in a variety of eukaryotic systems. A recent analysis of the genomic location of human microRNA genes suggested that 50% are located in cancer-associated genomic regions or fragile sites [3, 4]. Recently, Calin et al. identified mutations in six microRNA genes (miR-16-1, miR-27b, miR-29b2/29a, miR122a, miR-187, miR-206) in patients with Chronic Lymphocytic Leukemia (CLL) [5]; none of these mutations were found in a set of 160 individuals without cancer (P < .0001) [5]. One germline mutation, miR16-1 C > T + 7, resulted in reduced expression of miR-16-1 both in vitro and in vivo. Since miR16-1 induces apoptosis by repressing bcl-2, a decrease in miR16-1 will result in bcl-2 overexpression, which is a common feature in CLL [6]. Previous data indicated that miR16-1 and miR15a behave as tumor suppressors in CLL. The combination of loss of heterozygosity plus a germline mutation in this region is consistent with the Knudson Model of inactivation of a tumor suppressor gene. Thus, the presence of deleterious mutations in miR-15a and miR-16-1 suggests that this new class of RNAs may play a significant role in many sporadic and hereditary cancers. miR-15a and miR-16-1 are located on chromosome 13q14.3 close to BRCA2, which is frequently mutated in hereditary breast and ovarian cancers, and Rb, which is deleted or mutated in retinoblastoma and sarcomas. In fact, one of the individuals with CLL in which the mutation was identified reported a family history of breast cancer. Perhaps the mutation in miR16-1 can interact with inactivation of miR16-1 to modify the clinical phenotype [7]. Several cancers, including nasopharyngeal and HCC, have a high frequency of LOH near miR15a/miR16-1. Shao et al. found that 78% of nasopharyngeal tumors had LOH at 13q [8]; another group found that the highest frequency of LOH in nasopharyngeal cancer was at loci D13S133 (53.6%) on 13q14.3 [9]. In HCC, LOH at subchromosomal regions 13q12.3-14.1 and 13q32 was significantly associated with advanced tumor stage and larger tumor size [10]. Further, homozygous deletion of 13q12.11 was significantly associated with early onset HCC [11]. Finally, since there are no data on the miR 16 C > T + 7 mutation in CML, these patients were included in this study. We genotyped 1428 biological samples including tissue and blood DNA from a total of 1365 patients diagnosed with different types of cancer, including breast and ovarian cancers, HCC, CML, CLL nasopharyngeal carcinoma, and retinoblastoma using a TaqMan assay for the miR16-1 gene C > T substitution.
###end p 4
###begin title 5
2. Materials and Methods
###end title 5
###begin p 6
###xml 544 551 544 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 1169 1176 1169 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR16-1</italic>
###xml 1869 1871 1869 1870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 1911 1913 1910 1911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 1959 1961 1957 1958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
###xml 747 755 <span type="species:ncbi:9606">patients</span>
###xml 791 799 <span type="species:ncbi:9606">patients</span>
###xml 828 836 <span type="species:ncbi:9606">patients</span>
###xml 989 997 <span type="species:ncbi:9606">patients</span>
The study population consisted of 188 breast carcinomas (108 cases without and 80 cases with a family history of breast and ovarian cancer), 102 ovarian cancer (23 cases without and 79 cases with a family history of breast or ovarian cancer), 96 HCC, 22 nasopharyngeal carcinoma, 872 CML, 39 CLL, and 46 sporadic retinoblastoma cases. For some sporadic breast and ovarian cases both blood and tissue DNA was tested (40 of 108 sporadic breast and 23 of 23 sporadic ovarian cancer patients) for a total of 1428 specimens belonging to 1365 cases (Table 1). The HCC cases were recruited between December, 1998 and July, 2005 from an HCC endemic region in southern China. Tissue specimens from ovarian, and nasopharyngeal carcinomas and retinoblastoma patients and blood samples from CML and CLL patients were collected from Turkish patients in the Oncology Institute, University of Istanbul between 1991 and 2000. Samples from breast carcinoma cases were collected in two independent studies; patients were of Turkish (Oncology Institute) and American origin (Columbia University Medical Center) and collected between 1991-2005 and 1995-2005, respectively. Analysis of the miR16-1 gene C > T substitution was performed using the 5' nuclease TaqMan SNP genotyping assay. TaqMan primers and probes were designed by Applied Biosystems Inc. (ABI, Foster City, Calif, USA) with sequence data from the Sanger Center Website (http://www.sanger.ac.uk/Software/Rfam/mirna/). The probes were labeled with either FAM or VIC; allele a specific hybridization and degradation allowed for discrimination of the mutated versus the wild type sequence. As a control, two 100 bp synthetic oligonucleotides (Invitrogen, Carisbad, Calif, USA) corresponding to either the wild type or mutant sequence were used to verify the specificity of the probes. The reactions were prepared as follows: 10 muL of TaqMan Universal Master Mix, in 20 muL final reaction volumes, with 20 ng DNA, 0.2 muL TaqMan SNP Genotyping Assay Mix (80X) resulting in a final concentration of 900 nmol/L for the primers, and 200 nmol/L of the probes. Thermal cycling conditions were 95degreesC for 10 minutes, and then 40 cycles of 95degreesC for 15 seconds and 60degreesC for 1 minute. Thermal cycling was performed on an ABI-Realtime 7500 system using the absolute quantitation program standard with ABI SDS software version 1.2.3. Each 96-well plate contained 92 test samples and four reaction controls, including nontemplate, synthetic oligonucleotide homozygous for the C, or T allele and synthetic oligonucleotides combined to make a heterozygote.
###end p 6
###begin title 7
3. Results and Discussion
###end title 7
###begin p 8
###xml 573 580 573 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR16-1</italic>
###xml 163 168 <span type="species:ncbi:9606">human</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
MicroRNAs can be involved in cancer initiation and progression and their expression profiling can be exploited for the classification, diagnosis, and prognosis of human malignancies. In addition, germline and somatic mutations in several miRNAs seem to contribute to cancer pre-disposition and progression. To understand this, we searched 1428 biological specimens including tissue and blood DNA from a total of 1365 patients diagnosed with different types of cancer, including breast and ovarian cancers, HCC, CML, CLL, nasopharyngeal carcinoma and retinoblastoma for the miR16-1 (C > T) + 7 mutation.
###end p 8
###begin p 9
We did not detect any mutations in the 1428 samples from 1365 cases analyzed. Our study encompassed a wide range of cancer types including solid tumors (breast, ovarian, nasopharyngeal and HCC), leukemias (CML, CLL) and a childhood cancer (retinoblastoma). We also analyzed DNA samples from individuals representing several ethnicities including American (primarily Caucasian), Chinese and Turkish, and in some cases' (breast and ovarian) individuals with and without a family history of cancer.
###end p 9
###begin p 10
###xml 35 43 35 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-16-1</italic>
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR15a</italic>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 259 266 259 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-15a</italic>
###xml 271 279 271 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-16-1</italic>
###xml 404 411 404 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR16-1</italic>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 551 553 551 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rb</italic>
###xml 660 672 660 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR16-1 gene</italic>
###xml 1002 1004 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1121 1122 1121 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
###xml 622 630 <span type="species:ncbi:9606">patients</span>
###xml 907 911 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 938 943 <span type="species:ncbi:9606">human</span>
###xml 1212 1220 <span type="species:ncbi:9606">patients</span>
###xml 1654 1662 <span type="species:ncbi:9606">patients</span>
The germline mutation found in the miR-16-1 and miR15a primary precursor caused low levels of microRNA expression in vitro and in vivo and was associated with deletion of the normal allele in CLL [5]. However, results have not been consistent [12]. MicroRNAs miR-15a and miR-16-1 are located in the region of a deletion at 13q13.4. This region is frequently deleted or downregulated in CLL cells and the miR16-1 (C > T) + 7 germ line mutation was found in one of the familial CLL patients who also had a family history of breast cancer [5]. BRCA2 and Rb, mutated in hereditary breast and ovarian cancer and retinoblastoma patients, are relatively close to the miR16-1 gene, and some tumors such as nasopharyngeal and HCC have some LOH in the region suggesting that the miR16-1 C > T + 7 mutation may be important in other cancers. A miR16-1 mutation in the 3' flanking region was recently identified in NZB mice that serve as a model for human CLL, further supporting a unique role for miR16-1 in CLL [13], and it was shown that the C > T substitution on miR16-1 gene affects the level of expression of mature microRNAs [5]. The percentage of mutation in CLL was 2.6% in the study of Calin et al. and one of the patients was a hereditary CLL case and had a familial history of breast cancer history. Moreover, we did not identified any miR16-1 C > T + 7 mutation in our CLL subgroup of cases who had no hereditary CLL and cancer history in their family. Our results for miR16-1 C > T + 7 mutation in CLL are concordant with the study of Borkhardt et al. The frequency of mutation can be different for a particular population and hereditary background of patients and ethnicity can affect the results.
###end p 10
###begin p 11
Our results suggest that mutation of miRNA 16-1 is not informative as a prognostic and diagnostic risk factor for the different types of cancers we studied. miR16-1 C > T + 7 mutation may be important in other solid tumors such as colorectal and lung cancer and especially B-cell Non Hodgkin lymphoma which arise from the same progenitor branch of cell lineage as CLL.
###end p 11
###begin title 12
4. Conclusions
###end title 12
###begin p 13
In our large scale study with representation from different ethnicities and with various levels of hereditary risk, we did not identify any cases with the miR-16-1 (C > T) + 7 mutation in any of the cancers tested. However, we tested for the presence of only one type of mutation in one miRNA gene. Many miRNA genes have been investigated for different type of mutations in different type of cancer. Therefore, further research is necessary to determine the importance of the distribution of miRNA mutations in carcinogenesis.
###end p 13
###begin title 14
Acknowledgments
###end title 14
###begin p 15
H. Yazici is the recipient of an Avon Foundation-AACR International Scholar Award in Breast Cancer Research. This work was supported by NIH grants ES09089 and CA013696.
###end p 15
###begin article-title 16
MicroRNAs: small RNAs with a big role in gene regulation
###end article-title 16
###begin article-title 17
MicroRNAs: genomics, biogenesis, mechanism, and function
###end article-title 17
###begin article-title 18
Mammalian microRNAs: a small world for fine-tuning gene expression
###end article-title 18
###begin article-title 19
Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
###end article-title 19
###begin article-title 20
A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia
###end article-title 20
###begin article-title 21
miR-15 and miR-16 induce apoptosis by targeting BCL2
###end article-title 21
###begin article-title 22
The retinoblastoma protein binds the promoter of the survival gene bcl-2 and regulates its transcription in epithelial cells through transcription factor AP-2
###end article-title 22
###begin article-title 23
High frequency loss of heterozygosity on the long arms of chromosomes 13 and 14 in nasopharyngeal carcinoma in Southern China
###end article-title 23
###begin article-title 24
Two distinct regions of deletion on chromosome 13q in primary nasopharyngeal carcinoma
###end article-title 24
###begin article-title 25
Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma
###end article-title 25
###begin article-title 26
###xml 46 51 <span type="species:ncbi:9606">human</span>
Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11
###end article-title 26
###begin article-title 27
MicroRNA in chronic lymphocytic leukemia
###end article-title 27
###begin article-title 28
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 76 80 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice
###end article-title 28
###begin p 29
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Distribution of cancer patients in the study.
###end p 29
###begin p 30
###xml 47 59 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#167;</sup>
 *42 Caucasian, 34 Hispanic, 2 Asian, 2 other, section signCaucausian
###end p 30
###begin p 31
NA; material not avaible, ND; not detected.
###end p 31

